Future of Glucagon-like Peptide 1 Market: Size, Share & Forecasts to 2029

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

What Is the Projected Market Size Valuation of the Glucagon-like Peptide 1 Market by 2025?
The market size of glucagon-like peptide 1 has experienced a robust growth in the past few years. It is projected to increase from $20.88 billion in 2024 to $22.06 billion in 2025, progressing at a compound annual growth rate (CAGR) of 5.7%. Growth factors during the historic period include the escalating occurrence of diabetes, intensified focus on superior diabetes management, patient's inclination towards injectable treatments, clinical effectiveness and safety parameters, as well as advancements made in diabetes research.

What Is the Estimated Market Growth Value for the Glucagon-like Peptide 1 Industry in 2029?
In the coming years, the glucagon-like peptide 1 market is projected to experience robust expansion, reaching an estimated value of $30.5 billion by 2029, with a compound annual growth rate (CAGR) of 8.4%. The predicted growth within this period is due to the introduction of oral glp-1 treatments, emphasis on personalized healthcare, incorporation in diabetes management protocols, and a focus on patient-oriented healthcare strategies. In the forecast period, key trends include market outreach in developing economies, approval of new formulations by regulations, an increased concentration on personalized healthcare, enhancement of patient knowledge through educational and awareness programs, and dynamics of competitive market landscape.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report

What Are the Growth Drivers and Opportunities in the Glucagon-like Peptide 1 Market?
The upward trend in diabetes prevalence is predicted to boost the worldwide market for glucagon-like peptide 1. Diabetes is a health condition characterized by high levels of blood glucose or sugar. Glucagon-like peptide 1 is a prescribed medication for conditions such as type 2 diabetes, potentially aiding weight loss and lowering blood sugar levels. To illustrate, the National Library of Medicine, a US hub for biomedical informatics and computational biology, estimated in January 2022 that the global prevalence of diabetes in individuals aged between 20-79 was 10.5% (536.6 million people) in 2021, with forecasts showing an increase to 12.2% (783.2 million) by 2045. Hence, the rising incidence of diabetes is set to stimulate the glucagon-like peptide 1 market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10830&type=smp

What Are the Primary Segments Covered in the Global Glucagon-like Peptide 1 Market Report?
The glucagon-like peptide 1 market covered in this report is segmented -

1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By End-Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:
1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)
2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)
3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)
4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems

What Are the Top Growth Trends in the Glucagon-like Peptide 1 Market?
The surge in technological advancement is a significant trend taking over the global glucagon-like peptide 1 market. To retain their foothold in the market, leading companies are introducing groundbreaking technologies. For example, Novo Nordisk A/S, the acclaimed pharmaceutical company based in Denmark, introduced Wegovy in March 2024. This is the solitary, once-weekly glucagon-like peptide 1 treatment meant for weight control. Wegovy emerged successful and was proven safe and well-tolerated in the STEP Phase 3a clinical trial program. The product assists individuals dealing with obesity in attaining and sustaining weight reduction.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=10830&type=smp

Which Companies Are Shaping the Future of the Glucagon-like Peptide 1 Market?
Major companies operating in the glucagon-like peptide 1 market include Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals

Which Region Holds the Largest Market Share in the Glucagon-like Peptide 1 Industry?
North America was the largest region in the glucagon-like peptide 1 market in 2024. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.